Australia Insulin Infusion Pump Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia insulin infusion pump market is shifting from stand-alone pumps towards connected systems that adjust insulin automatically from sensor readings. Recurring consumables now generate more revenue than hardware, and each new sensor listing changes which pump a user can choose.

Three forces are shaping demand: federal subsidy design, with pump consumables partly subsidised through the National Diabetes Services Scheme while pumps themselves are funded privately or through a young-person program; rapid sensor and software turnover; and a growing pay-as-you-go option that lowers the upfront cost of tubeless pumps.

In March 2025, Insulet made Omnipod 5 commercially available in Australia, and in August 2025 the Swiss owner of the mylife YpsoPump business changed hands. In August 2026 the government appointed Diabetes Australia to run the Insulin Pump Program, and in October 2026 a standalone 15-day sensor widened pump-sensor choice.

Key Market Trends and Insights

• Funding gap: The National Diabetes Services Scheme partly subsidises pump consumables, but pumps themselves are not subsidised, so private health cover and self-funding decide who gets a device, as updated in July 2026.
• Young-person pathway: Diabetes Australia took over the government-funded Insulin Pump Program in August 2026, with a household income threshold of AUD 123,078 and a limited annual supply of pumps for people under 21.
• Sensor pairing: The July 2026 compatibility chart pairs each pump with specific sensors, so the removal of an older Dexcom sensor in October 2026 forces switching and software support across pump brands.
• Tubeless momentum: Insulet reported on 5 August 2026 that international Omnipod revenue reached USD 251.8 million, up 35.5%, showing how quickly the pay-as-you-go tubeless model is spreading outside the United States.

Australia Insulin Infusion Pump Market Size and Forecast

The market is moving from conventional tubed pumps towards tubeless systems and hybrid closed-loop control, with recurring consumables providing a steady revenue base. Patch pumps and closed-loop systems lead growth, while infusion sets, cartridges and reservoirs remain the largest line because every tubed pump user reorders them. Private health insured adults form the largest group, while self-funded and pay-as-you-go users expand fastest. Queensland grows quickest, with New South Wales the largest state. Sensor listings, subsidy settings and software updates support a durable, multi-year outlook.

Key Takeaways: Australia Insulin Infusion Pump Market

Consumables and Connected Pumps Anchor Demand

Revenue is on course to roughly double across the decade, from AUD 205.00 million in 2025 to AUD 422.51 million in 2035 at a 7.5% CAGR. Recurring consumable orders and sensor-linked software make demand repeat-driven rather than replacement-driven.

Tubeless and Closed-Loop Systems Lead Growth

Patch pump systems and pods grow at an estimated 11.0% CAGR and hybrid closed-loop systems at an estimated 9.5% CAGR through 2035. Self-funded and pay-as-you-go users rise at 9.0% as buyers avoid large upfront pump costs.

Insulin Pump Program Handover Changes Access

Diabetes Australia was appointed in August 2026 to run the government-funded program for three years, replacing the previous provider. Applications were paused during the handover and are expected to reopen later in 2026.

• Pumps are fully subsidised for eligible people under 21
• The single available pump is the mylife YpsoPump with CamAPS FX
• Consumables and sensors are obtained through the scheme

Australia Insulin Infusion Pump Market Report Summary

Key Insight

Funding rules, sensor compatibility and the move to automated control shape the outlook. Recurring consumables hold the revenue base, while tubeless and closed-loop systems carry growth.

Key Trends in the Australia Insulin Infusion Pump Market

The Australia insulin infusion pump market is being reshaped by sensor listings, forced product transitions and subsidy changes that tie each pump to specific continuous glucose monitors.

October 2026 - FreeStyle Libre 3 Plus Opens to Pump-Free Use and More Pump Brands

• From 1 October 2026 the Abbott FreeStyle Libre 3 Plus is subsidised through the scheme for all Australians with type 1 diabetes, including those not using a linked pump.
• Diabetes Australia said in September 2026 that the mylife Loop system already works with the sensor, while Omnipod 5 compatibility was still to be announced.
• Sensors last 15 days and up to six can be ordered per transaction.

September 2026 - Guardian System (4) Transmitter Ends and MiniMed 780G Becomes the Sole Guardian Route

• The scheme stopped supplying the Guardian System (4) transmitter, code 985, on 1 September 2026, as announced on 28 July 2026.
• The Guardian Sensor (4) is now approved only with Guardian Link (4) inside a pump system, meaning the MiniMed 780G.
• Medtronic offered eligible registrants no-cost sensor supply during the transition.

July 2026 - National Compatibility Chart Maps Each Pump to Its Approved Sensors

• Version 20 of the scheme chart, dated 1 July 2026, links the t:slim X2 to Dexcom G6 and G7, and Omnipod 5 to Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus.
• The same chart pairs the MiniMed 780G with Guardian Link (4) and the mylife YpsoPump with Dexcom G6, Dexcom G7 and FreeStyle Libre 3 Plus.
• The scheme announced on 10 July 2026 that Dexcom G6 would end on 1 October 2026.

December 2025 - Libre 3 Plus Becomes Subsidised for mylife YpsoPump Users

• The scheme announced on 17 November 2025 that FreeStyle Libre 3 Plus would be subsidised from 1 December 2025 for people using the mylife YpsoPump with CamAPS FX.
• Sensors are available only to these pump users, with code 996 and up to six sensors per order.
• The co-payment was AUD 17.35 per sensor where one applies.

Key Insight

Sensor and pump choices now move together. Listings, withdrawals and longer-wear sensors push users towards integrated systems, and each change creates switching appointments and fresh consumable demand.

Recent Market Developments in the Australia Insulin Infusion Pump Market

Recent developments, presented from the most recent, show the Australia insulin infusion pump market moving through a program handover, strong tubeless sales and ownership changes among pump suppliers.

August 2026 - Diabetes Australia Appointed to Run the Insulin Pump Program

• Diabetes Australia announced on 17 August 2026 that it will run the Commonwealth-funded Insulin Pump Program for three years, taking over from Breakthrough T1D Australia.
• Applications were closed during the handover and are expected to reopen later in 2026, with existing applicants and waitlist places transferred.
• Eligibility requires being under 21, Medicare eligibility, and household income of AUD 123,078 or less.

August 2026 - Insulet Reports Faster International Omnipod Growth

• Insulet reported on 5 August 2026 second-quarter revenue of USD 801.7 million, up 23.5%.
• International Omnipod revenue reached USD 251.8 million, up 35.5%, or 32.9% in constant currency.
• Omnipod 5 has been commercially available in Australia since March 2025 with Dexcom G6 and G7.

March 2026 - MiniMed Completes Initial Public Offering on Nasdaq

• MiniMed priced its offering on 6 March 2026 at USD 20 per share, raising about USD 560 million in gross proceeds.
• Medtronic holds about 90.03% of the common stock after the offering and continues the separation of the business.
• A focused listed owner can speed investment in the MiniMed 780G system used in Australia.

January 2026 - mylife Diabetes Care Completes Separation as an Independent Company

• On 30 January 2026 mylife Diabetes Care announced that its move to a standalone company was complete, following the August 2025 sale of the business by Ypsomed to TecMed AG.
• The company supplies the mylife Loop system, combining the YpsoPump with CamAPS FX.
• It also runs a patch pump program and plans a pairing with Abbott's future glucose and ketone sensor.

Key Insight

Recent events show access and ownership being rearranged. A program handover, a new public listing and a supplier separation sit alongside strong tubeless sales, while eligibility rules stay unchanged.

Australia Insulin Infusion Pump Industry Segmentation

The Expert Market Research’s report on the Australia Insulin Infusion Pump Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Infusion Sets, Cartridges and Reservoirs
• Patch Pump Systems and Pods
• Tubed Insulin Pumps
• Others

Infusion Sets, Cartridges and Reservoirs lead revenue, since the scheme partly subsidises these consumables for pump users and a July 2026 update confirmed the access rules. Patch Pump Systems and Pods grow fastest at an estimated 11.0% CAGR through 2035, helped by Omnipod 5 pod codes for Dexcom G7, Libre 2 Plus and Dexcom G6 users. Tubed Insulin Pumps, including the t:slim X2, MiniMed 780G and mylife YpsoPump, rise at 5.0% as replacements follow warranty cycles. Others covers controllers, software subscriptions, adhesives and carry accessories at 7.0%.

Market Breakup by Technology

• Hybrid Closed-Loop Systems
• Low-Glucose Suspend Systems
• Standalone Pump Therapy
• Others

Hybrid Closed-Loop Systems lead and grow fastest at an estimated 9.5% CAGR through 2035, because the MiniMed 780G, Omnipod 5, Control-IQ on the t:slim X2 and the mylife Loop all adjust insulin automatically. Low-Glucose Suspend Systems decline gradually at an estimated 2.5% as users upgrade to full automation. Standalone Pump Therapy grows slowest at 1.5%, retained by users who prefer manual control or lack a compatible phone, a reason Abbott kept the Libre 2 Plus listed after the October 2026 Libre 3 Plus launch.

Market Breakup by Funding Pathway

• Private Health Insured Adults
• Insulin Pump Program Recipients
• Self-Funded and Pay-As-You-Go Users
• Others

Private Health Insured Adults lead, since insurers fund much of the upfront cost of pumps that the scheme does not subsidise. Insulin Pump Program Recipients are young people under 21, supplied one model, the mylife YpsoPump, by a program Diabetes Australia took over in August 2026. Self-Funded and Pay-As-You-Go Users grow fastest at an estimated 9.0% CAGR, aided by an Omnipod 5 subscription priced at AUD 185 a month in July 2026. Others covers public hospital supply, veterans' arrangements and workplace-funded purchases at 5.5%.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest resident population and the main clinic network, growing at an estimated 7.2% CAGR through 2035. Victoria follows at 7.4%, and Melbourne hosted the IDF-WPR and Australasian Diabetes Congress from 18 to 21 August 2026. Queensland is the fastest-growing state at an estimated 8.0%, ahead of Western Australia at 7.8%, where Diabetes WA will submit sensor forms from 1 October 2026. South Australia grows at 7.0%. Others covers Tasmania, the Australian Capital Territory and the Northern Territory at 7.6%, where remote access to specialists limits uptake.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Insulin Infusion Pump Market

Competition combines pump makers, sensor partners and consumable suppliers. Entry barriers include therapeutic goods registration, scheme listing, sensor and app compatibility, clinician training and local support teams.

Insulet

Insulet, headquartered in Acton, Massachusetts, makes the tubeless Omnipod 5 and Omnipod DASH systems. Omnipod 5 became commercially available in Australia in March 2025 with Dexcom G6 and G7, and the scheme lists pod codes for Dexcom G7, Libre 2 Plus, Dexcom G6 and DASH. Insulet reported international Omnipod revenue of USD 251.8 million in the second quarter, up 35.5%, in August 2026. Subsidy access requires registration with Insulet Australia.

Medtronic

Medtronic, headquartered in Dublin, Ireland, supplies the MiniMed 780G pump system in Australia through Medtronic Australasia, paired with the Guardian Link (4) sensor connection. Its Guardian System (4) transmitter ended on 1 September 2026, leaving the pump as the only Guardian route. The MiniMed diabetes business listed on Nasdaq in March 2026, and Medtronic retains about 90.03% of the shares.

Tandem Diabetes Care

Tandem Diabetes Care, headquartered in San Diego, California, offers the t:slim X2 pump with Control-IQ automated insulin delivery. The scheme chart of July 2026 lists compatibility with Dexcom G6 and Dexcom G7 for Australian users. In July 2026 the company announced Libre 3 Plus integration in five European markets, but Australia was not among them, so local sensor choice remains narrower than for rival pump brands.

mylife Diabetes Care

mylife Diabetes Care, owned by TecMed AG after Ypsomed completed the sale of its diabetes business in August 2025, makes the mylife YpsoPump and operates mylife Diabetes Care Australia from Sydney. It is the sole pump in the Insulin Pump Program and works with CamAPS FX. Freestyle Libre 3 Plus became subsidised for its users in December 2025, and the mylife App is scheduled to be phased out on 1 December 2026.

Other players operating in the Australia insulin infusion pump market include Dexcom, Abbott, Roche Diabetes Care, Medtrum Technologies, and Sequel Med Tech, alongside diabetes educators, pharmacies and NDSS Access Points supporting pump training, consumable supply and sensor access across Australia.

Key Insight

Competition rests on sensor compatibility, algorithm quality, funding access and clinical support rather than price. Global pump makers hold the installed base, while newer entrants compete through ease of use.